FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and aims at treatment of cancer. N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ilcarbonylamino] ethoxy}benzamide of formula (I): 
or its salt connection with a pharmaceutically acceptable acid or base, separately or in combination with the surgical intervention, chemotherapy, hormonal therapy or radiation therapy is administered for 4 days running, followed by 3 days running without using said compound, at the same time chemotherapy is not FOLFOX.
EFFECT: invention ensures increased human cancer treatment efficiency.
10 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| METHODS OF APPLYING (+)-1,4-DIHYDRO-7-[(3S, 4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(THIAZOLYL)-1,8-NAPHTHIRIDINE-3-CARBOXYLIC ACID FOR CANCER TREATMENT | 2006 |
|
RU2592231C2 |
| METHODS OF APPLYING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THUASOLYL)-1,8-NAPHTHYDIRINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER | 2006 |
|
RU2428983C2 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
| SELECTIVE ANTAGONISTS OF EP4 RECEPTOR FOR CANCER TREATMENT | 2010 |
|
RU2563817C2 |
| COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
| TREATMENT OF PANCREATIC CANCER | 2018 |
|
RU2792690C2 |
| METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH LSD1, LSD1 INHIBITORS | 2020 |
|
RU2826217C1 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| METHOD OF TREATING SQUAMOUS CELL CANCER OF ANAL CANAL | 2011 |
|
RU2459644C1 |
